All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Mutation testing in AML:
What you need to know
with Charles Craddock, Ralph Hills, and Gail Roboz
Wednesday, April 23, 2025
17:30-18:30 BST
This independent educational activity is supported by Thermo Fisher Scientific. All content is developed independently by the faculty. The funder is allowed no influence on the content.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Investigational new drug application for VOR33 cleared by the FDA
By Claire Baker
Bookmark this article
On January 14, 2021, the U.S. Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for VOR33 in patients at risk of relapse with acute myeloid leukemia (AML).
VOR33
The engineered hematopoietic stem cell (eHSC) therapy, VOR33, involves reconstitution with cells lacking CD33. The rationale behind this is to allow for subsequent treatment with the CD33-directed antibody–drug conjugate, gemtuzumab ozogamicin, while limiting myelosuppression and the resulting toxicities.
The clearance of the IND application allows the initiation of a phase I/IIa trial, which will evaluate the safety and feasibility of VOR33 in patients with CD33+ AML who will likely relapse. Investigators hope to determine whether VOR33 can engraft sufficiently. Following successful engraftment, enrolled patients will be offered treatment with gemtuzumab ozogamicin, with the hope to improve leukemia-free survival.
HSC with VOR33 may be an effective approach in achieving hematopoietic reconstitution that is resistant to CD33-targeted therapies, thereby improving posttransplant outcomes in patients with AML.
Vorbio. Vor announces FDA clearance of IND application for VOR33. https://www.vorbio.com/vor-announces-fda-clearance-of-ind-application-for-vor33/. Published Jan 14, 2021. Accessed Jan 15, 2021.
More about...
Your opinion matters
3 votes - 17 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox